OBI Pharma USA

7 articles about OBI Pharma USA

• Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)

  1/8/2024

  The Partner of Biosion Inc., OBI Pharma, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody drug conjugate cancer therapy targeting TROP2.

• OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

  1/3/2024

  OBI Pharma, a clinical stage oncology company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody - drug conjugate cancer therapy targeting TROP2.

• OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

  4/10/2023

  OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.

• 

  Liver Cancer Insight Report: Current Therapies, Drug Pipeline and Outlook

  1/29/2020

  Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...

• OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

  9/3/2019

  First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on multiple tumor types   [03-September-2019]   TAIPEI, Taiwan , Sept. 3, 2019 /PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an

• OBI Pharma, Inc. to Present at the 37th J.P. Morgan Healthcare Conference

  1/8/2019

  OBI Pharma, Inc. announced that Amy Huang, General Manager, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:00 a.m. PST/12 noon EST, in San Francisco, CA.

• OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

  9/19/2018

  Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme